iRhythm targets wider monitoring reach and sets 2026 and 2027 benchmarks
iRhythm (IRTC) is focusing on Zio Monitor in primary care and VitalConnect, with 2026 revenue guidance of $890–$895 million.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
iRhythm Technologies (IRTC) is building its growth plans around expanding Zio Monitor into primary care, scaling MCT through VitalConnect and pursuing adjacent markets, according to TradingView. The company's revenue guidance for fiscal 2026 is between $890 million and $895 million.
Among its 2027 priorities are Zio Monitor growth of roughly 15% and an adjusted EBITDA margin just above 15%. The publisher notes that the text is an AI-generated summary that may contain inaccuracies, so key figures should be checked against the original source.
why it matters
For investors, the revenue guidance and margin target show how much the company expects sales and profitability to grow as its ambulatory heart-rhythm monitoring business expands. The 2027 benchmarks give a reference point for judging the business's next stage.
market impact
IRTC shares: growth plans and revenue guidance set expectations for the company
tags
instruments
sources
- IRTC: Primary-care expansion and VitalConnect aim to drive monitoring growth and broader MCT reach — TradingView, 19 November 2026 at 12:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗